Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Change in Receivables (2016 - 2023)

Palisade Bio has reported Change in Receivables over the past 13 years, most recently at $250000.0 for Q1 2023.

  • Quarterly Change in Receivables changed N/A to $250000.0 in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $334000.0 through Mar 2024, up 21.45% year-over-year, with the annual reading at -$84000.0 for FY2021, 242.37% down from the prior year.
  • Change in Receivables was $250000.0 for Q1 2023 at Palisade Bio, up from $84000.0 in the prior quarter.
  • Over five years, Change in Receivables peaked at $250000.0 in Q1 2023 and troughed at -$108751.0 in Q3 2019.
  • The 5-year median for Change in Receivables is -$32545.0 (2019), against an average of -$1916.1.
  • Year-over-year, Change in Receivables soared 181.1% in 2020 and then plummeted 2778.05% in 2021.
  • A 5-year view of Change in Receivables shows it stood at -$40090.0 in 2019, then surged by 114.97% to $6000.0 in 2020, then crashed by 1083.33% to -$59000.0 in 2021, then surged by 242.37% to $84000.0 in 2022, then surged by 197.62% to $250000.0 in 2023.
  • Per Business Quant, the three most recent readings for PALI's Change in Receivables are $250000.0 (Q1 2023), $84000.0 (Q4 2022), and -$59000.0 (Q3 2021).